For years, the comparison between tirzepatide and semaglutide relied on cross-trial guesswork. Different patient populations, different protocols, different endpoints. You could squint at the numbers and make an argument either way.
That changed with SURMOUNT-5.
The First Head-to-Head Trial
Published in late 2024, SURMOUNT-5 enrolled 751 adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition. Half got tirzepatide (up to 15mg). Half got semaglutide 2.4mg (the max approved dose for weight loss). Both groups titrated to their maximum tolerated dose over 72 weeks.
This was the trial everyone had been waiting for. Same patients. Same timeline. No more guessing.
The Results
The tirzepatide group lost 22.5% of their body weight. The semaglutide group lost 15.0%.
That's a 47% greater reduction with tirzepatide. In absolute terms, if you weighed 250 pounds, that's roughly 56 pounds with tirzepatide versus 37.5 pounds with semaglutide. Almost 20 pounds of difference.
At the highest response tier, 26.6% of tirzepatide patients lost 30%+ of their body weight. Only 8.2% of semaglutide patients hit that mark.
Why the Difference?
Tirzepatide is a dual-agonist. It activates both GIP and GLP-1 receptors. Semaglutide only activates GLP-1.
Think of it like this: semaglutide presses one lever that reduces appetite and slows gastric emptying. Tirzepatide presses that same lever plus a second one (GIP) that independently improves insulin sensitivity and may affect how your body stores and burns fat.
The GIP receptor piece is still being studied, but the clinical outcomes are hard to argue with.
Side Effect Comparison
GI side effects — nausea, diarrhea, vomiting, constipation — were the most common adverse events in both groups. SURMOUNT-5 showed comparable rates between the two, with tirzepatide patients reporting slightly higher rates of diarrhea and semaglutide patients reporting slightly more nausea.
Serious adverse events occurred at similar rates: roughly 5-7% in both groups. Discontinuation due to side effects was also similar, around 3-4% for each.
Neither drug had concerning signals for pancreatitis, thyroid issues, or gallbladder disease beyond what prior trials had established.
Cost Comparison
Brand-name pricing makes both drugs expensive. Zepbound (tirzepatide) lists around $1,000-1,100/month. Wegovy (semaglutide) lists around $1,300-1,400/month.
Compounded versions change the math. Compounded tirzepatide typically runs $97-200/month depending on dose. Compounded semaglutide runs $150-350/month. These prices vary by pharmacy and provider.
Both brand-name versions have manufacturer savings programs and occasional insurance coverage, but the landscape is unpredictable.
Who Should Choose Which?
Tirzepatide makes more sense if
You have a significant amount of weight to lose (50+ pounds), you have insulin resistance or type 2 diabetes, or you want the strongest clinical response the data supports.
Semaglutide might be preferable if
You've already been on it and it's working well, your insurance covers Wegovy but not Zepbound, or you have a specific medical reason your doctor recommends it.
Either way
Both drugs produce clinically meaningful weight loss. Semaglutide's 15% average is still remarkable by historical standards. The "best" drug is the one you can access, afford, and tolerate.
The Honest Bottom Line
Tirzepatide won the head-to-head. The margin wasn't close. But semaglutide is still a genuinely effective medication that's changed millions of lives. If you're choosing between them, the data favors tirzepatide — but access and cost matter too.